tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors.
By S. Berghmans, R. Murphey, Erno Wienholds, D. Neuberg, J. Kutok, C. Fletcher, John P. Morris, Tingxi Liu, S. Schulte-Merker, J. Kanki and 3 more. Proceedings of the National Academy of Sciences of the United States of America, 2005
618 citations recorded by the source corpus.
TP53 is the most frequently mutated tumor suppressor gene in human cancer, with nearly 50% of all tumors exhibiting a loss-of-function mutation. To further elucidate the genetic pathways involving TP53 and cancer, we have exploited the zebrafish, a powerful vertebrate model system that is amenable to whole-genome forward-genetic analysis and synthetic-lethal screens. Zebrafish lines harboring missense mutations in the tp53 DNA-binding domain were identified by using a target-selected mutagenesis strategy. Homozygous mutant fish from two of these lines were viable and exhibited mutations similar to those found in human cancers (tp53(N168K) and tp53(M214K)). Although homozygous tp53(N168K) mutants were temperature-sensitive and suppressed radiation-induced apoptosis only at 37 degrees C, cells in the tp53(M214K) embryos failed to undergo apoptosis in response to gamma radiation at both 28 and 37 degrees C. Unlike wild-type control embryos, irradiated tp53(M214K) embryos also failed to up-regulate p21 and did not arrest at the G(1)/S checkpoint. Beginning at 8.5 months of age, 28% of tp53(M214K) mutant fish developed malignant peripheral nerve sheath tumors. In addition to providing a model for studying the molecular pathogenic pathways of malignant peripheral nerve sheath tumors, these mutant zebrafish lines provide a unique platform for modifier screens to identify genetic mutations or small molecules that affect tp53-related pathways, including apoptosis, cell-cycle delay, and tumor suppression.
Subfields: Cancer Research, Neurology, Oncology
View Paper: https://www.semanticscholar.org/paper/18d8660a3df9a0bcc0a17a5d6738de4791c0fe48
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- MicroRNA-125b is a novel negative regulator of p53. (2009, background): “866 GENES & DEVELOPMENT p53M214K mutant, which is defective in p53 activity but still undergoes normal embryogenesis (Berghmans et al. 2005).”
- p53 Activation by Knockdown Technologies (2007, methodology): “The p53 knockdown by itself does not induce any significant defects, as p53 is not required for normal development in mammals or fish [17,18] (Figures 1B and 2B).”
- Animal models of human disease: zebrafish swim into view (2007, background): “, which is a lymphocyte V(D)J recombinase associated with human severe combined immunodeficiency, and the tumour suppressor genes p53 (Ref”